Last €24.07 EUR
Change Today +0.065 / 0.27%
Volume 460.0
EUZ On Other Exchanges
Symbol
Exchange
OTC US
Xetra
As of 12:15 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

eckert & ziegler strahlen un (EUZ) Snapshot

Open
€23.99
Previous Close
€24.01
Day High
€24.23
Day Low
€23.97
52 Week High
01/20/14 - €30.67
52 Week Low
03/14/14 - €22.55
Market Cap
127.4M
Average Volume 10 Days
5.0K
EPS TTM
€1.72
Shares Outstanding
5.3M
EX-Date
05/23/14
P/E TM
14.0x
Dividend
€0.60
Dividend Yield
2.49%
Current Stock Chart for ECKERT & ZIEGLER STRAHLEN UN (EUZ)

Related News

No related news articles were found.

eckert & ziegler strahlen un (EUZ) Related Businessweek News

No Related Businessweek News Found

eckert & ziegler strahlen un (EUZ) Details

Eckert & Ziegler Strahlen & Medizintechnik AG, together with its subsidiaries, provides isotope technology for medical, scientific, and industrial use. The company operates through four segments: Radiation Therapy, Isotope Products, Radiopharma, and Environmental Services. The Radiation Therapy segment produces and distributes medical devices for brachytherapy, which is a form of radiotherapy that treats cancer by irradiation from a short distance. It offers radioactive small implants for treating prostate gland cancer on the basis of iodine-125; and tumor irradiators on the basis of Cobalt-60 or Iridium-192. This segment’s products and equipment are intended for use by oncologists, radio- therapists, urologists, ophthalmologists, and medical physicists. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. This segment offers custom and one-off design and manufacturing services. The Radiopharma segment operates in the field of molecular imaging and nuclear medicine supplying various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. It offers products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. The Environmental Services segment collects, measures, sorts, treats, and packs low level radioactive waste from hospitals, research institutes, and industry for its final disposal. The company markets its products through its sales offices, and a network of distributors and agents worldwide. Eckert & Ziegler Strahlen & Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.

Founded in 1992

eckert & ziegler strahlen un (EUZ) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €629.0K
Member of the Executive Board
Total Annual Compensation: €437.0K
Member of the Executive Board
Total Annual Compensation: €300.0K
Compensation as of Fiscal Year 2012.

eckert & ziegler strahlen un (EUZ) Key Developments

Eckert & Ziegler Strahlen & Medizintechnik AG Reports Earnings Results for the Full Year 2013; Provides Financial Guidance for Fiscal Year 2014

Eckert & Ziegler Strahlen & Medizintechnik AG reported earnings results for the full year 2013. For the period, the company showed a slight decrease in sales from EUR 120 to EUR 117 million. The decisive factors for this development were the decline in sales in industrial components, implants and instruments, the planned exit from the accessories trade in France as well as the unfavorable EUR/USD exchange rate. Additional sales from acquisitions were unable to compensate for these effects. Consolidated net profit after taxes and minority interests fell by 12% from EUR 10.3 million to EUR 9.1 million, and earnings per share dropped EUR 0.23 per share to EUR 1.72. The main reason for this was the decline in the gross margin, which was down 12% due to one-off effects although sales only registered a 2% decline. Higher sales costs as a result of higher one time waste costs as well as a shift in the product mix to low-margin products were also responsible. Overall, sales and earnings are expected to see at least 10% growth in fiscal year 2014. This corresponds to sales of some EUR 129 million and net profit of around EUR 10 million (EPS approx. EUR 1.90 per share) for the year. Internal planning figures are considerably higher than these threshold values.

Eckert & Ziegler Strahlen- und Medizintechnik AG to Recommend Dividend Payment

Eckert & Ziegler Strahlen- und Medizintechnik AG announced that at the General Shareholders' Meeting to be held on 22 May 2014, the Executive Board and the Supervisory Board will propose a dividend of EUR 0.60 per share entitled to a dividend compared with previous year dividend of EUR 0.60 per share.

Eckert & Ziegler Strahlen & Medizintechnik AG, 2013 Earnings Call, Mar 27, 2014

Eckert & Ziegler Strahlen & Medizintechnik AG, 2013 Earnings Call, Mar 27, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EUZ:GR €24.07 EUR +0.065

EUZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $26.71 USD +0.59
Nordion Inc C$12.50 CAD +0.09
View Industry Companies
 

Industry Analysis

EUZ

Industry Average

Valuation EUZ Industry Range
Price/Earnings 14.1x
Price/Sales 1.1x
Price/Book 1.5x
Price/Cash Flow 14.1x
TEV/Sales 0.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECKERT & ZIEGLER STRAHLEN UN, please visit www.ezag.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.